Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.26 is 31% above its 5-year average of -0.37, near the high end of its 5-year range (-0.54–-0.26).
18.55% above its 12-month average of -0.32.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 33 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.26
EARNINGS PER SHARE (EPS) AVG TTM
-0.32
EARNINGS PER SHARE (EPS) AVG 3Y
-0.33
EARNINGS PER SHARE (EPS) AVG 5Y
-0.37
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.55%
CURRENT VS 3Y AVG
+21.91%
CURRENT VS 5Y AVG
+30.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cardiol Therapeutics Inc.
Market Cap
$152.74M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$151.52M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$154.07M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$151.12M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.70
3Y Avg
-0.76
5Y Avg
-0.63
Market Cap
$155.86M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.05
3Y Avg
-0.06
5Y Avg
-0.06
Market Cap
$149.15M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$148.36M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$147.97M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$158.32M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $152.74M | -0.26 | -0.32 | -0.33 | -0.37 |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | -0.26 | -0.53 | -0.57 | -0.55 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.07M | -1.13 | -2.24 | -2.81 | -2.43 |
| Codexis, Inc. (CDXS)vs › | $151.12M | -0.34 | -0.70 | -0.76 | -0.63 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | -0.05 | -0.06 | -0.06 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.15M | -1.64 | -1.85 | -1.46 | -1.46 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | -0.61 | -0.35 | -0.32 | -0.30 |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | -0.51 | -0.38 | -0.76 | -1.59 |
| Inogen, Inc. (INGN)vs › | $158.32M | -0.90 | -1.19 | -2.61 | -1.83 |
| Minerva Neurosciences, Inc. (NERV)vs › | $158.63M | -28.87 | -17.24 | -11.28 | -9.01 |
Trailing EPS (TTM)
$-0.26
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.28 |
| 2024-12-31 | -0.35 |
| 2023-12-31 | -0.33 |
| 2022-12-31 | -0.36 |
| 2020-12-31 | -0.54 |
| 2019-12-31 | -0.41 |
| 2018-12-31 | -0.48 |
| 2017-12-31 | -0.06 |
